Scarica l'app Stockscreener
286.98
2.20%
-6.47
Dopo l'orario di chiusura:
288.00
1.02
+0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$293.45
Aprire:
$294.78
Volume 24 ore:
1.15M
Relative Volume:
0.99
Capitalizzazione di mercato:
$38.32B
Reddito:
$4.29B
Utile/perdita netta:
$577.22M
Rapporto P/E:
68.19
EPS:
4.2086
Flusso di cassa netto:
$641.34M
1 W Prestazione:
-2.74%
1M Prestazione:
-13.92%
6M Prestazione:
-36.11%
1 anno Prestazione:
+1.26%
Intervallo 1D:
$286.76
$298.00
Intervallo di 1 settimana:
$284.28
$298.38
Portata 52W:
$280.60
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors - simplywall.st
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Alnylam (NASDAQ: ALNY) director exercises 11,250 stock options at $70.20 - Stock Titan
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy? - Insider Monkey
Capital World Investors holds 10.9M Alnylam shares (NASDAQ: ALNY) - Stock Titan
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Capital Research holds 9.47M shares of Alnylam (NASDAQ: ALNY) in 13G/A - Stock Titan
Alnylam Pharmaceuticals stock (US02005N1000): Backs TTR revenue outlook amid AMVUTTRA growth - AD HOC NEWS
5 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts - Insider Monkey
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build - sharewise.com
ALNY: Strong AMVUTTRA growth, ambitious pipeline, and robust cash position drive future expansion - TradingView
Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY) - Insider Monkey
Alnylam Pharmaceuticals stock (US02005N1000): Q1 earnings beat and vutrisiran data - AD HOC NEWS
Alnylam (ALNY) Reports Positive Phase 3 Results for Vutrisiran i - GuruFocus
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden - BioSpace
Heart drug vutrisiran tied to fewer deaths in ATTR-CM patients - Stock Titan
How Alnylam’s Swing to Quarterly Profitability Could Reshape the Outlook for Alnylam Pharmaceuticals (ALNY) Investors - simplywall.st
Behavioral Patterns of ALNY and Institutional Flows - Stock Traders Daily
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves - simplywall.st
Alnylam surges after its Pfizer-rivaling blockbuster jumps nearly 200% - MSN
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam to Webcast Presentations at Upcoming Investor ConferencesMay 7, 2026 - BioSpace
Heart drug vutrisiran shows steady profile in new analyses - Longevity.Technology
FDA’s Untitled Letter tells Alnylam its Amvuttra survival claims don’t quite add up - Medical Marketing and Media
Porphyria Treatment Market to Reach USD 2.56 Billion by 2033 - openPR.com
Tenaya (NASDAQ: TNYA) trims R&D burn and signs Alnylam research pact - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) trims Q1 loss, lands Alnylam deal - Stock Titan
Alnylam Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
FMR LLC amends Schedule 13G to show 14.64M ALNY shares (NASDAQ: ALNY) - Stock Titan
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
H.C. Wainwright reiterates Alnylam stock rating on strong TTR sales - Investing.com
H.C. Wainwright reiterates Alnylam stock rating on strong TTR sales By Investing.com - Investing.com Canada
Competitive Landscape: Leading Companies and Emerging Competitors in the Vutrisiran Market - openPR.com
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Alnylam Pharmaceuticals (ALNY) Valuation After Q1 2026 Profit Breakthrough And Revenue Surge - simplywall.st
MSN Money - MSN
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM - BioSpace
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $429 - Moomoo
Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc - Moomoo
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Navigating a 51.79% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Alnylam Pharmaceuticals Q1 2026 earnings preview - MSN
Should Alnylam’s Billion‑Dollar Quarter and Return to Profitability Require Action From Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Hussman Strategic Advisors Inc. Buys Shares of 6,300 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Danske Bank A S - MarketBeat
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $370 to $500 - Moomoo
Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY) - The Globe and Mail
Alnylam Pharma (ALNY) Gets a Buy from Bernstein - The Globe and Mail
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 06 '26 |
Sale |
330.42 |
2,286 |
755,329 |
9,443 |
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 02 '26 |
Sale |
319.59 |
1,624 |
519,014 |
11,729 |
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):